After its anti-amyloid antibody birtamimab missed its primary endpoint in the Phase III AFFIRM-AL trial, Prothena is evaluating business options that include an “expected substantial workforce reduction,” the company announced May 23. The biotech will provide more details regarding the strategic review in June. Prothena in May announced that it would no longer invest in the development of its anti-amyloid antibody birtamimab after it failed the Phase III AFFIRM-AL trial in patients with AL amyloidosis.
